Last reviewed · How we verify
AKLIEF®
At a glance
| Generic name | AKLIEF® |
|---|---|
| Also known as | Trifarotene 0.005 % Topical Cream |
| Sponsor | Teva Pharmaceuticals USA |
| Target | Retinoic acid receptor alpha, Retinoic acid receptor beta, Retinoic acid receptor gamma |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Acne vulgaris
Common side effects
- Application site irritation
- Sunburn
- Application site pruritus
- Erythema
- Scaling
- Dryness
- Application site pain
- Application site dryness
- Application site discoloration
- Application site rash
- Application site swelling
- Application site erosion
Key clinical trials
- A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris (PHASE1)
- Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris (PHASE3)
- Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation (PHASE4)
- A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AKLIEF® CI brief — competitive landscape report
- AKLIEF® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI